The global cholesterol testing products and services market size was valued at USD 14.8 billion in 2018 and is expected to witness lucrative CAGR of 7.9% over the forecast period. Growing prevalence of high cholesterol levels is expected to drive the growth. Increasing awareness regarding routine screening of cholesterol level is another significant growth driver.
Rising prevalence of cardiovascular diseases and obesity is expected to significantly fuel the demand for cholesterol testing products and services. Population above 18 years of age is recommended to undergo blood cholesterol testing every five years. Patients with a history of heart attacks require cholesterol screening on a regular basis to monitor effectiveness of their treatment. As recommended by the National Heart, Lung, and Blood Institute, cholesterol testing should be done at least once between the age of 9 to 11 and 17 to 21.
As per the American Heart Association data published in 2017, around 29 million adult population in U.S. had total cholesterol levels higher than 240 mg/dL. According to the Centers for Disease Control and Prevention (CDC), adults between the ages of 40 to 59 have the highest level of total cholesterol, which is 17.1%. This is mainly attributed to the sedentary lifestyle leading to the development of numerous diseases, such as obesity, diabetes, and heart diseases. Increased awareness regarding routine testing and management of healthy cholesterol levels is anticipated to drive the demand for diagnostic products and services.
High cholesterol has no symptoms, hence there is a need for complete cholesterol testing. These tests include measurement of four types of lipids in the bloo- total cholesterol, high-Density Lipoprotein (HDL), low-Density Lipoprotein (LDL), and triglycerides. Blood cholesterol measurements aid in minimizing the risk of heart attack, stroke, and peripheral artery disease.
Rising geriatric population is another important cause for the rise in demand for cholesterol testing products and services. According to the Department of Economic and Social Affairs Population Division, global population aged 60 years and above increased from 9.2% in 1990 to 11.7% in 2013 and is expected to further increase to 21.1% by 2050. As per the data published by the United Health Foundation in 2017, 12.5% of people aged 60 years and above had high total cholesterol. Such high prevalence is expected to drive the market growth in near future.
Diagnostic centers dominated the market in 2018 in terms of total revenue share and is also anticipated to showcase the fastest CAGR over the forecast period owing to the rising number of people being diagnosed with high total cholesterol. In addition, regular health checkups without the doctors’ intervention is also a high impact-rendering driver for the segmental growth.
Government agencies segment is expected to witness significant growth over the forecast period due to their increasing focus on preventive care and early diagnosis to avoid serious disease conditions. The key market players work with federal, state, and local government agencies with an aim to provide quality diagnostic testing services across the world. In addition, Medicare and Medicaid benefits are expected to drive the segment growth in the forthcoming years.
North America held the largest revenue share in 2018 due to rise in prevalence of heart diseases and obesity in U.S. According to the United Health Foundation's annual report, in U.S., the obesity rate increased from 29.9% in 2017 to 31.3% in 2018. In addition, growing preference for preventive healthcare is also projected to drive the regional growth. Growing awareness and efforts from government and various organizations are expected to fuel the market growth.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rise in population in this region. Asia accounts for around 60% of the world’s population. Increasing cardiovascular diseases is another factor driving the regional market growth. Rise in the number of new diagnostic centers and pathological laboratories is also expected to foster the regional demand for cholesterol testing products and services.
Some of the key market players include Quest Diagnostics Incorporated; Cell Biolabs, Inc.; Bio-Reference Laboratories, Inc.; Spectra Laboratories, Inc.; Eurofins Scientific; Randox Laboratories Ltd.; Synlab International GmbH; Thermo Fisher Scientific; and Clinical Reference Laboratory, Inc.
Key companies focus on various strategic initiatives, such as regional expansion, product development, and strategic collaborations and partnerships. They are introducing new assay kits and reagents for cholesterol testing for rapid and easy diagnosis. For instance, in 2017, Quest Diagnostics introduced a novel, nonfasting cholesterol testing with improved LDL calculation method for improved accuracy and patient comfort.
Attribute |
Details |
Base year for estimation |
2018 |
Actual estimates/Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Market representation |
Revenue in USD Million & CAGR from 2019 to 2026 |
Regional scope |
North America, Europe, Asia Pacific, Latin America & MEA |
Country scope |
U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, Japan, India, China, South Korea, Singapore Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global cholesterol testing products and services market report on the basis of type of customer and region:
Type of Customer Outlook (Revenue, USD Million, 2015 - 2026)
Diagnostic Centers
Physicians/Providers and Hospitals
Government Agencies
Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Russia
Asia Pacific
Japan
China
India
South Korea
Australia
Singapore
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
b. The global cholesterol testing products and services market size was estimated at USD 15.7 billion in 2019 and is expected to reach USD 16.8 billion in 2020.
b. The global cholesterol testing products and services market is expected to grow at a compound annual growth rate of 7.9% from 2019 to 2026 to reach USD 26.8 billion by 2026.
b. North America dominated the cholesterol testing products and services market with a share of 37.4% in 2019. This is attributable to rise in prevalence of heart diseases and obesity in U.S., growing preference for preventive healthcare, and growing awareness and efforts from government and various organizations.
b. Some key players operating in the cholesterol testing products and services market include Quest Diagnostics Incorporated; Cell Biolabs, Inc.; Bio-Reference Laboratories, Inc.; Spectra Laboratories, Inc.; Eurofins Scientific; Randox Laboratories Ltd.; Synlab International GmbH; Thermo Fisher Scientific; and Clinical Reference Laboratory, Inc.
b. Key factors that are driving the market growth include growing prevalence of high cholesterol levels, increasing awareness regarding routine screening of cholesterol level, and rising geriatric population.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.